Open access

Targeting DNMT1 augments anti-tumor CD8⁺ T cell function

M. Deshmukh Danielle K. Sohai Kamal Obbad Koonam Park S. Milette Peili Gu Henna S. Nam Andrew J Daniels K. Spasov Michael E. Hurwitz Samuel G. Katz R. Flavell Karen S. Anderson M. Bosenberg Goran Micevic

Jul 2026 · bioRxiv · 0 citations · 23 references

Biology Medicine

TL;DR

DNMT1 targeting is established as a promising strategy to counteract CD8⁺ T cell exhaustion and potentiate ICI efficacy and enhances the effector function of melanoma patient-derived tumor infiltrating lymphocytes after prolonged ex vivo expansion.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Review Aug 2026

Targeting T-cell exhaustion and tumour immune evasion: a review of emerging strategies.

A complementary therapeutic strategy is discussed: engineering T cells for greater durability in the TME through knockout of exhaustion-associated transcription factors, and reprogramming tumour cells with DNA methyltransferase (DNMTi) and histone deacetylase (HDACi) inhibitors to restore immunogenicity.

L. Saltis, Liew Jun Mun · Pathology, Research and Prac... · 0 citations

Open access Jul 2026

Epigenetic reprogramming of terminal T cell differentiation via DNMT1 inhibition reverses terminal DNA methylation and enhances multipotency 2259880

An epigenetic approach is described that facilitates the reversal of repressive DNA methylation and is used to alter the fate of T cell subsets for immunotherapy and is now used to alter the fate of T cell subsets for immunotherapy.

A. Norman, Ben Youngblood, Caitlin C. Zebley · Journal of Immunology · 0 citations

Jul 2026

CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer.

These findings highlight Dusp5 and Zfp219 as critical drivers of age-related T cell dysfunction that can be targeted to rejuvenate antitumor immunity in older cancer patients.

Alex C. Y. Chen, Keely Y. Ji, C. Yerinde et al. · Cell · 0 citations

Open access Jul 2026

Targeting a cancer cell Interferon-TBK1 signaling axis attenuates inflammatory memory mediated resistance to immune checkpoint blockade 2257735

It is observed that ex vivo JAKi and TBK1i treatment, in a cancer cell intrinsic manner, induces a more stem-like CD8 T cell response following ICB, possibly through improved interactions with myeloid cells.

Nathan Dangle, Jingya Qiu, D. Ye et al. · Journal of Immunology · 0 citations

Sep 2026

Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis.

These findings define MDACs as an immunogenic myeloid subset and establish myeloid reprogramming as a strategy to improve radiotherapy-immunotherapy outcomes.

Fei Ji, Lei Zheng, Da-Peng Chen et al. · Cancer Cell · 0 citations

Sep 2026

Aging rewires genetic dependencies in antitumor T cells.

The aged tumor microenvironment can impair antitumor T cell function, but the molecular regulators that become limiting in this setting remain poorly defined. In a recent issue of Cell, Chen and colleagues harness in vivo CRISPR screening to compare the effects of genetic perturbations in tumor-reactive CD8+ T cells ac...

Brian Oh, Corina Amor · Cancer Research · 0 citations